- Home
- ICCM vs RPTX Comparison
ICCM vs RPTX Comparison
Compare ICCM & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- RPTX
- Stock Information
- Founded
- ICCM 2006
- RPTX 2016
- Country
- ICCM Israel
- RPTX Canada
- Employees
- ICCM N/A
- RPTX N/A
- Industry
- ICCM
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- RPTX Health Care
- Exchange
- ICCM Nasdaq
- RPTX Nasdaq
- Market Cap
- ICCM 61.0M
- RPTX 58.8M
- IPO Year
- ICCM N/A
- RPTX 2020
- Fundamental
- Price
- ICCM $1.05
- RPTX $1.37
- Analyst Decision
- ICCM Strong Buy
- RPTX Strong Buy
- Analyst Count
- ICCM 1
- RPTX 3
- Target Price
- ICCM $2.50
- RPTX $4.50
- AVG Volume (30 Days)
- ICCM 254.9K
- RPTX 178.8K
- Earning Date
- ICCM 05-28-2025
- RPTX 05-13-2025
- Dividend Yield
- ICCM N/A
- RPTX N/A
- EPS Growth
- ICCM N/A
- RPTX N/A
- EPS
- ICCM N/A
- RPTX N/A
- Revenue
- ICCM $3,273,000.00
- RPTX $1,073,000.00
- Revenue This Year
- ICCM $85.75
- RPTX N/A
- Revenue Next Year
- ICCM $189.92
- RPTX N/A
- P/E Ratio
- ICCM N/A
- RPTX N/A
- Revenue Growth
- ICCM 0.34
- RPTX N/A
- 52 Week Low
- ICCM $0.48
- RPTX $0.89
- 52 Week High
- ICCM $1.66
- RPTX $4.29
- Technical
- Relative Strength Index (RSI)
- ICCM 46.97
- RPTX 55.96
- Support Level
- ICCM $0.99
- RPTX $1.33
- Resistance Level
- ICCM $1.14
- RPTX $1.41
- Average True Range (ATR)
- ICCM 0.07
- RPTX 0.06
- MACD
- ICCM 0.01
- RPTX -0.01
- Stochastic Oscillator
- ICCM 64.00
- RPTX 55.56
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.